There was a significantly higher Objective Response Rate (ORR) (p=0.001) and 49% reduced cumulative risk of progression in the liver as first event (HR: 0.51; p<0.001) among the patients treated with SIR-Spheres® Y-90 resin microspheres.
Wasan HS et al. Lancet Oncol 2017; 18: 1159-71.